ITP Safety

For your adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment
 

 

SAFETY AND TOLERABILITY PROFILE DEMONSTRATED IN MULTIPLE CLINICAL TRIALS1

Adverse reactions with a frequency ≥10% in patients with chronic ITP treated with DOPTELET—pooled data from clinical trials*

 

Adverse
Reaction
DOPTELET
(N=128)
%
Placebo
(N=22)
%
Headache 31 14
Fatigue 28 9
Contusion 26 18
Epistaxis 19 18
Upper Respiratory
Tract Infection
15 5
Arthralgia 13 0
Gingival Bleeding 13 0
Petechiae 11 9
Nasopharyngitis 10 0

 

*The safety of DOPTELET in adults with chronic ITP was evaluated in two Phase 3 trials (one randomized, double-blind, placebo-controlled trial, and one randomized, double-blind, active-controlled trial) and two Phase 2 trials (one randomized, double-blind, placebo-controlled, dose-ranging trial and one open-label extension trial) in 161 patients with chronic ITP. Analysis included 128 patients who received 2.5 to 40 mg of DOPTELET once daily for a median exposure of 29.1 weeks, and 22 patients who received placebo for a median exposure of 5.9 weeks.1,2

 

Icon: Swoosh
DOPTELET Efficacy

Discover how DOPTELET increased platelet counts in the clinical trial.1

SEE THE DATA

 

References:

1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc; 2019.

2. Data on file. Dova Pharmaceuticals, Inc.